Welcome to our dedicated page for Ardelyx SEC filings (Ticker: ARDX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ardelyx, Inc. (Nasdaq: ARDX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a biopharmaceutical issuer with commercial products IBSRELA and XPHOZAH and an active development pipeline, Ardelyx uses SEC reports to describe its financial condition, risk factors, governance and material corporate events.
Current reports on Form 8-K referenced in recent disclosures cover topics such as quarterly financial results, amendments to loan and security agreements, changes to equity incentive plans and bylaws, and transitions in senior management roles. For example, Ardelyx has filed 8-Ks describing appointments and resignations of executive officers, the approval of amendments to its 2014 Equity Incentive Award Plan at the annual meeting of stockholders, and changes to its loan facilities, including new term loans and updated maturity dates.
On this page, users can also locate periodic reports such as Forms 10-K and 10-Q, which contain detailed financial statements, management’s discussion and analysis, descriptions of the company’s products IBSRELA and XPHOZAH, discussions of its NHE3 inhibitor pipeline and summaries of key risks related to drug development and commercialization. These filings provide context for revenue from tenapanor-based products, licensing arrangements with partners such as Kyowa Kirin, Fosun Pharma and Knight Therapeutics, and capital structure information.
Stock Titan enhances access to Ardelyx filings with AI-powered summaries that highlight important sections in lengthy documents, such as annual reports on Form 10-K and quarterly reports on Form 10-Q. Users can also review filings related to executive compensation, equity plans and governance changes, as disclosed in proxy materials and associated 8-Ks. Real-time updates from the EDGAR system help ensure that new Ardelyx filings, including future 8-Ks reporting material events, are reflected promptly for investors and researchers.
Ardelyx, Inc. (ARDX) reported an insider stock sale by its president and CEO, who is also a director. On 11/21/2025, the executive sold 46,887 shares of common stock at $5.5369 per share. According to the filing, this sale was made under an automatic sell-to-cover feature tied to restricted stock unit (RSU) awards and was done solely to cover withholding taxes due at vesting.
After this transaction, the executive beneficially owns 1,455,363 shares of Ardelyx common stock directly. In addition, 24,364 shares are held in a living trust and 1,000 shares are held in trusts for the executive’s children, both reported as indirect ownership.
Ardelyx, Inc. (ARDX) reported an insider equity transaction by its Chief Business Officer, Mike Kelliher. On 11/21/2025, he sold 5,560 shares of common stock at a price of $5.5369 per share. The company states these shares were sold automatically upon the vesting of restricted stock units to cover applicable withholding taxes, rather than as a discretionary sale.
Following this transaction, Kelliher directly beneficially owns 271,181 shares of Ardelyx common stock. The filing is a Form 4 submitted for one reporting person and reflects a routine tax-related sale connected to equity compensation.
Ardelyx, Inc. (ARDX) reported an insider share sale by its Chief Patient Officer, Laura A. Williams. On 11/21/2025, Williams sold 6,426 shares of Ardelyx common stock at a price of $5.5369 per share. The filing explains that this was a sell-to-cover transaction imposed by the terms of the original restricted stock unit ("RSU") awards and that the shares were sold solely to cover applicable withholding taxes when the RSUs vested.
Following this tax-related sale, Williams beneficially owned 359,896 shares of Ardelyx common stock, held in direct ownership. The transaction was reported on a Form 4 filed for a single reporting person.
Ardelyx, Inc. (ARDX) reported a Form 4 filing for its Chief Commercial Officer, who is an officer but not a 10% owner. On 11/21/2025, the officer sold 5,814 shares of Ardelyx common stock at a price of $5.5369 per share. According to the explanation, the sale was an automatic sell-to-cover triggered by the vesting of restricted stock units, with shares sold solely to cover withholding taxes. Following this transaction, the officer directly beneficially owns 295,684 shares of Ardelyx common stock.
Ardelyx, Inc. (ARDX) reported an insider equity transaction by Senior Vice President of Finance Joseph J. Reilly. On 11/21/2025, he sold 11,086 shares of common stock at an average price of $5.5369 per share. Following this transaction, he beneficially owned 108,914 shares directly.
The sale was executed pursuant to an automatic sell-to-cover feature tied to previously granted restricted stock units. When the RSUs vested, a portion of the resulting shares was automatically sold to cover applicable withholding taxes, rather than as a discretionary sale of shares.
Ardelyx (ARDX) — Initial ownership filing. CFO Susan Hohenleitner reported 146,896 RSUs, each deliverable as one share of common stock upon vesting. She also holds a stock option for 578,104 shares at an exercise price of $5.01, expiring 10/13/2035. Twenty five percent of the option vests on 10/13/2026, with the remainder vesting in 36 equal monthly installments, subject to continued service.
Ardelyx, Inc. filed a Form S-8 registering 10,000,000 shares of common stock for issuance under its Amended and Restated 2014 Equity Incentive Award Plan, resulting from an increase approved by stockholders on June 18, 2025.
The registration becomes effective upon filing, with sales to occur as awards under the plan are exercised and/or vest. This filing also references and builds on prior S-8 registrations for the 2014 Plan and the ESPP. Standard indemnification, incorporation-by-reference, and exhibit items are included.
Ardelyx reported Q3 results with total revenues of $110,329 thousand. Product sales, net were $105,515 thousand, led by IBSRELA at $78,158 thousand (up 92% year over year), while XPHOZAH contributed $27,357 thousand and reflected lower demand and price following its inclusion in the ESRD Prospective Payment System.
Operating expenses were $101,679 thousand. Net loss was $969 thousand. The quarter included $4,789 thousand of non-cash royalty revenue from Japan partner Kyowa Kirin, including a commercialization milestone of approximately $3.4 million tied to a ¥500.0 million trigger.
Cash, cash equivalents and short-term investments were $242,705 thousand as of September 30, 2025. Long-term debt was $202,138 thousand after drawing a $50,000 thousand Term E Loan on June 30, 2025, with options for an additional $100,000 thousand in committed term loans. Shares outstanding were 242,971,838 as of September 30, 2025.
Ardelyx, Inc. filed a current report stating that on October 30, 2025 it announced its financial results for the quarter ended September 30, 2025. The company furnished the full text of the related earnings press release as Exhibit 99.1, rather than treating it as filed, which affects how it may be used in future securities law filings. The report also notes the inclusion of an Inline XBRL cover page data file as Exhibit 104.
Ardelyx (ARDX) reported an initial Form 3 for a company officer. The filing lists 218,000 shares of Common Stock tied to restricted stock units, each RSU settling into one share upon vesting. It also discloses a stock option for 327,000 shares at an exercise price of $4.49, expiring on 07/14/2035.
Per the vesting terms, 25% of the option vests on 07/14/2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to continued service. The reporting person is identified as the company’s Chief Technical Operations Officer, and the event date is 08/01/2025.